Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Almac extends Pharma Services business unit to increase demand for storage capacity

Almac extends Pharma Services business unit to increase demand for storage capacity

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios commences KB004 Phase 1 trial in patients with leukemia

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

SGEN, Abbott enter collaboration agreement for ADC products

SGEN, Abbott enter collaboration agreement for ADC products

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Shanghai ChemPartner signs outsource research service agreement with Shenogen Pharma

Shanghai ChemPartner signs outsource research service agreement with Shenogen Pharma

Ventana, CST enter license agreement for personalized cancer diagnostics

Ventana, CST enter license agreement for personalized cancer diagnostics

Millennium, SGEN expand ADC collaboration

Millennium, SGEN expand ADC collaboration

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

New study: Two peptide agent combination might block tumor growth

New study: Two peptide agent combination might block tumor growth

Scientists identify strategy for targeted molecular therapy in liver cancer

Scientists identify strategy for targeted molecular therapy in liver cancer

Gamida to distribute Health Robotics' CytoCare, i.v.STATION, i.v.SOFT technologies in Israel

Gamida to distribute Health Robotics' CytoCare, i.v.STATION, i.v.SOFT technologies in Israel

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

New PTLD Guideline highlighted at NCCN Annual Conference

New PTLD Guideline highlighted at NCCN Annual Conference

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

Simcere files IND with SFDA of China for APX003 to treat cancer

Simcere files IND with SFDA of China for APX003 to treat cancer

Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma

Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.